DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)
The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies…
Small Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Small-Cell Lung Cancer (US)
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (…
Small Cell Lung Cancer – Current Treatment – Treatment Sequencing – Small-Cell Lung Cancer (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Breast Cancer – Unmet Need – Unmet Need – Metastatic Triple-Negative Breast Cancer (US/EU)
The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have…
